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Summary Acidic fibroblast growth factor (FGF1) and two of its receptors, FGFR1 and FGFR4, were localized in cryostat sections of normal,
benign and malignant human breast tissue by immunohistochemistry. Without pretreatment, FGF1 staining was mainly seen in normal
epithelial cells. However, polymerase chain reaction (PCR) analysis and immunoblotting of isolated normal epithelial and myoepithelial cells
showed FGF1 mRNA and protein to be present in both cell types. Following incubation of frozen sections at 370C in phosphate-buffered
saline, FGF1 staining was also revealed in myoepithelial cells and basement membrane adjacent to carcinoma cells. Treatment with protease
inhibitors demonstrated that this effect was due to the activity of an endogenous protease. In contrast, FGF1 staining was found to be
associated with the stroma adjacent to malignant cells only in the presence of protease inhibitors. FGFR1 and FGFR4 immunostaining was
localized to both normal and malignant epithelial cells and to a lesser extent to myoepithelial cells. There was no difference in the staining
intensity for the FGF receptors between normal and cancer samples. The change in location of FGF1 between normal and malignant tissues
and the sensitivity of stored FGF1 to the action of endogenous proteases raises the possibility of both autocrine and paracrine roles for FGF1
in the normal and malignant human breast.
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Fibroblast growth factor 1 (FGF1) belongs to a family of multi-
functional polypeptides that are involved in a wide array of
biological processes, which include cellular proliferation and
differentiation, angiogenesis, chemotaxis, embryonal development
and tissue repair (Basilico and Moscatelli, 1992). To date, the
FGFs consist of a family of nine homologous polypeptide growth
factors that include FGF1 (acidic FGF), FGF2 (basic FGF), FGF3
(int-2), FGF4 (hst-l/Kaposi FGF), FGF5, FGF6 (hst-2), FGF7
(keratinocyte growth factor), FGF8 (androgen-induced growth
factor) and FGF9 (glial-activating factor) (Basilico and Moscatelli,
1992; Tanaka et al, 1992; Miyamoto et al, 1993). These proteins
share 35-50% overall homology of their amino acid sequences
(Basilico and Moscatelli, 1992; Givol and Yayon, 1992).
Unlike othermembers ofthe family, FGF1, FGF2 and FGF9 are
synthesized without a signal peptide sequence and thus may
remain sequestered in the cell (Basilico and Moscatelli, 1992; Cao
and Pettersson, 1993). However, release of FGF may occur
through leakage from damaged cells or from viable cells via a
novel mechanism (Mignatti et al, 1992; Cao andPettersson, 1993).
Yeoman (1993) has postulated that proteoglycan-bound FGF may
be released from the cell surface or extracellular matrix by the
action of proteases, and Briozzo et al (1991) have shown that
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MCF7 breast cancer cells secrete cathepsin D, which is able to
digest the extracellular matrix and release stored FGF2, which was
then intemalized by the MCF7 cells.
As FGFI was first purified from brain tissue (Thomas et al,
1984) it is not surprising that its localization was primarily identi-
fied in neural tissue such as brain (Fallon et al, 1992; Stock et al,
1992), spinal cord (Koshinaga et al, 1993), optic nerve (Faucheux
et al, 1992) and the eye (Caruelle et al, 1989). Hughes and Hall
(1993) conducted a large immunohistochemical study of normal
human adult tissues using a polyclonal antibody to FGF1. Their
results show intense staining for FGFI in the heart, glomerula of
the kidney, urothelium and placenta and moderate immunoreac-
tivity in a wide range oftissues, including breast glandular epithe-
lium. In the normal virgin mouse mammary gland, high levels of
FGF1 mRNA were found in partially purifiedbreast organoids and
had identical expression to cytokeratin 18, a specific marker for
epithelial cells. Normal stroma contained little FGF1 mRNA and
there was a lower level ofexpression in tumorigenesis (Coleman-
Krnacik and Rosen, 1994). We have previously shown that FGF1
and FGF2 are both present in human breast tissue (Gomm et al,
1991; Luqmani et al, 1992a; Smith et al, 1994) and that they are
both mitogenic for breast cancer cell lines (Smith et al, 1994;
Johnston et al, 1995). Our studies measuring FGF1 mRNA by
reverse transcriptase polymerase chain reaction (RT-PCR) and
protein levels by Westem blotting of breast tissue samples
suggested areduction in FGF1 synthesis in breast cancercompared
with normal breast tissue (Bansal et al, 1995). Similar mRNA
results have also been demonstrated using Northem blotting by
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Anandappa et al (1994). Using immunostaining techniques, we
have localized FGF2 in the myoepithelial cells in paraffin sections
of normal breast, but we did not find it in normal or malignant
epithelial cells (Gomm et al, 1991), and in a preliminary study we
demonstrated staining for FGF1 in normal but not malignant
breast epithelial cells (Bansal et al, 1995). We have also detected
FGF1 in the conditioned medium from breast tumour biopsies,
using a bioassay system, but we were unable to specify whether
the signal was produced by tumour cells or by a stromal element
(Smith et al, 1994). This breast cancer conditioned-medium
was also found to be mitogenic for breast cancer cell lines
(Smith et al, 1994).
The response of cells to extracellular FGFs is thought to be
mediated through the formation of a ternary complex of FGF,
heparan sulphate proteoglycan and high-affinity plasma
membrane receptor (Klagsbrun andBaird, 1991; Givol andYayon,
1992). The high-affinity receptors for FGF belong to the tyrosine
kinase superfamily of receptors. So far, receptors encoded by at
least four separate genes (FGFR1-4) have been identified
(Basilico and Moscatelli, 1992; Givol and Yayon, 1992; Jaye et al,
1992; Partanen et al, 1992). This family of receptors is further
complicated by an array ofspliced variants that vary in their extra-
or intracellular domains, resulting in potentially truncated forms
(Givol and Yayon, 1992; Jaye et al, 1992; Partanen et al, 1992).
The function of most of these receptor isoforms is unknown. We
have demonstrated the presence ofFGFR1 and FGFR2 mRNA in
both normal and breast cancer samples as well as a panel ofbreast
cell lines and normal human tissues (Luqmani et al, 1992a), and
Jacquemier et al (1994) have also demonstrated the presence of
FGFR1 mRNA in normal and malignant breast epithelial cells
using in situ hybridization. Since then we have shown that breast
cancer tissues and cell lines express a preponderance of mRNA
and protein for the two-loop variant form ofFGFR1 as opposed to
the full-length three-loop form (Luqmani et al, 1995). Using
immunohistochemistry, Hughes and Hall (1993) have described
intense positivity for FGFR1 in breast tissues, which was found to
be localized within myoepithelial cells of normal breast samples.
To our knowledge no studies have as yet been published that
describe the localization of FGFR1 protein in breast cancer nor
FGFR4 protein in the normal or malignant breast.
In order to understand more fully the role of FGF1 in the
mammary gland we examined its localization and that oftwo ofits
receptors, FGFR1 and FGFR4 (Partanen et al, 1992), in a variety
ofhuman breast tissues. Immunostaining was carried out on cryo-
stat sections of 78 samples using our own specific monoclonal
antisera against FGF1 and FGFR1 and a commercial antibody
against FGFR4. To identify further the sites of FGF1 storage and
synthesis Western blotting and RT-PCR analyses were carried out
on purified populations ofnormal breast epithelial and myoepithe-
lial cells. In addition, we describe here a novel method for
assessing the activity of endogenous proteases on FGF1 distribu-
tion in frozen breast tissue.
MATERIALS AND METHODS
Antibodies
A mouse monoclonal antibody was raised against a synthetic
peptide, corresponding to amino acids 60-98 of the FGF1 mole-
cule. This sequence represents part ofthe FGF1 molecule that has
the least homology with FGF2. The antigen used to raise the
FGFR1 antibody was in an area of the molecule judged by
computer analysis to have high antigenicity and consisted of
amino acids 816-822 at the C-terminus ofFGFR1. This antibody
will detectboth alpha andbetaforms ofthe FGFR1 receptor. In the
case of FGFR4, the rabbit polyclonal antibody raised to amino
acids 789-802 was purchased from Santa Cruz Biotechnology.
Briefly, theFGF1 andFGFR1 peptides weresynthesizedusingthe
Fmoc method (Atherton and Sheppard, 1985). The peptides were
prepared using aNovaSyn Crystal automated peptide synthesizer on
a KA (Kieselguhr/polydimethyVacrylamide) resin (Calbiochem
Novabiochem) and peptide purity was checked by reverse-phase
high-performance liquid chromatography (HPLC). The peptides
were coupled to a purified protein derivative of tuberculin (PPD)
(Morrison et al, 1987) and were then injected into female Balb/c
mice. The spleen, from a selected mouse, was removed and the
splenocytes fusedwith Sp2/O myelomacells aspreviouslydescribed
(Galfre and Milstein, 1981). Hybridoma supematants were screened
by ELISA before selection for recloning, after which the antibodies
were isotyped and total IgG concentrations were evaluated.
Immunohistochemical staining for FGF1
Tissue from a total of 78 breast biopsies (Table 1) were immedi-
ately snap-frozen in liquid nitrogen and embedded in OCT
(Optimum cutting tissue) (Raymond A Lamb, London, UK).
Tissue sections (8-10 jim) were cut and mounted on Vectabond-
coated slides (Vector Labs, Peterborough, UK). Immunostaining
was performed using an indirect peroxidase technique. Briefly,
frozen sections were fixed in 3.7% formaldehyde in phosphate-
buffered saline (PBS) for 10 min and then treated with ice-cold
acetone, 50% followed by 100%, for 5 min each. Sections were
then washed in PBS (pH 7.2) before blocking with normal goat
serum (Vector) [10% in PBS with 5% bovine serum albumin
(BSA)] for 30 min at room temperature. This preincubation buffer
was then discarded and, without washing, sections were incubated
in the mouse monoclonal antibody to FGF1 (3 jg ml-') or non-
immune mouse IgG at the same concentration, diluted in blocking
buffer. After 90 min incubation at room temperature in a moist
chamber, sections were washed in PBS and incubated in anti-
mouse IgG peroxidase conjugate (Sigma Chemical, Poole, Dorset,
UK), at a dilution of 1:250 in PBS containing 5% BSA and 10%
normal human serum (Sigma). Sections were incubated for a
furthur90 minbefore washing inPBS andthe substrate was devel-
oped in a 0.05% solution of 3,3'-diaminobenzidine (Sigma).
Sections were counterstained in Gill's haematoxylin. To test the
Table 1 Histological diagnosis of breast tissue biopsies used in
immunostaining for FGF1, FGFR1 and FGFR4
Histological diagnosis FGF1 FGFR1/FGFR4
Normal 23 18
Fibroadenoma 9 6
Fibrocystic change 2 1
Lactating breast 1 1
Invasive ductal carcinoma 30 16
Invasive lobular carcinoma 3 3
Ductal carcinoma in situ 9 7
Mucinous carcinoma 1 0
Total numbers 78 52
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specificity ofthe anti-FGFI antibody, dilute antiserum, at a concen-
tration of3 gg ml-1, was incubated overnight at 4°C with an excess
(300 ,ug ml-') ofthe immunizing peptide, prior to immunostaining.
Immunohistochemical staining for FGFR1 and FGFR4
A three-stage avidin-biotin complex (ABC) immunoperoxidase
technique was used for the localization of FGFR1 and FGFR4.
Frozen sections were fixed in 3.7% formaldehyde in PBS for
10 min and permeabilized in ice-cold acetone, 50% followed by
100%, for 5 min each. Sections were then washed in PBS and
blocked for endogenous biotin following the protocol included
with a biotin blocking kit (Vector). After further washes in PBS,
sections were preincubated with normal goat serum (in the case of
FGFR4) or normal horse serum (in the case of FGFRl) (10% in
PBS with 5% BSA) for 30 min atroom temperature before incuba-
tion with the primary antibody (0.5 jg ml-1) or non-immune
mouse or rabbit IgG at equivalent concentrations, overnight at
4°C. The following day sections were washed and incubated in
biotinylated second antibodies (1:200, diluted in PBS with 10%
human serum) for 30 min and finally incubated in Vectastain ABC
reagent (Vector) for 1 h at room temperature. Staining was visual-
ized using 0.05% 3,3'-diaminobenzidine and counterstained with
Gill's haematoxylin.
Assay for endogenous proteases
Unfixed frozen sections were incubated in either PBS only at
pH 7.2 or the same buffer containing a mixture of the serine
protease inhibitors 6-aminohexanoic acid (100 mM), benzamidine
hydrochloride (5 mM) and phenylmethylsulphonylfluoride (PMSF)
(1 mM), the thiol protease inhibitor N-ethylmaleimide (1 mM)
and the metalloproteinase inhibitor disodium EDTA (10 mM) for
2 h at 37°C. Sections were then washed in three changes of PBS
and stained for FGF1 by the indirect peroxidase technique
described above.
RNA extraction, reverse transcription and PCR
amplification
Breast organoids were prepared from reduction mammoplasty
tissue as described previously (Gomm et al, 1995). From organoid
preparations we were then able to obtain purified populations of
epithelial and myoepithelial cells by immunomagnetic separation
(Gomm et al, 1995). PCR and immunostaining for the epithelial
and myoepithelial markers epithelial membrane antigen (EMA),
common acute lymphoblastic leukaemia antigen (CALLA) and
cytokeratins 18, 19 and 14 have shown these separated cell popu-
lations to be consistently 97-99% pure (Gomm et al, 1995).
mRNA from pure cell populations of epithelial and myoepithe-
lial cells were extracted using the Dynabeads mRNA Direct
kit (Dynal, UK). For reverse transcription (RT), first-strand
synthesis was carried out using Moloney murine leukaemia virus
(MMLV) reverse transcriptase and 2 jig of RNA in a volume
of20 ,l. An aliquot (1 pl) ofRT product was added to 99g1 ofthe
PCR mixture containing 1 unit of Taq polymerase, 200 ng each
of the actin primers 5'-CATCTCTTGCTCGAAGAAGTCCA-3'
and 5'-ATCATGTTTGAGACCTTCAA-3' plus 200 ng each of
either the FGF1 primers, 5'-GATGGCACAGTGGATGGGAC-3'
and 5'-AAGCCCGTCGGTGTCCATGG-3' or the FGFR1,
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Figure 1 Western immunoblots for FGF1. (A) Showing the specificity of the
anti-FGF1 monoclonal antibody for FGF1. Lane 1,15 ng of recombinant
FGF1; lane 2,15 ng of recombinant FGF2. In lanes 3 and 4,15 ng of FGF1
and FGF2 respectively were incubated with the monoclonal anti-FGF1
antibody, which had been preincubated with an excess of the immunizing
peptide. (B) Separated normal breast cell fractions incubated with anti-FGF1
antibody. E, epithelial cells; M, myoepithelial cells
5'-CCTCCTCTTCTGGGCTGTGCT-3' and 5'-TCTTTTCTGGG-
GATGTCC-3' or FGFR4 primers, 5'-GGTCCTGCTGAGTGT-
GCCTG-3' and 5'-GGGGTAACTGTGCCTATTCG-3'.
PCR products were chloroform extracted and 10 gl of each
sample was electrophoresed on 1% agarose gels and alkali blotted
overnight, for subsequent hybridization. The FGFI and actin
samples were hybridized to cDNA randomly labelled with
[aX-32P]dCTP, using the random primer method (Feinberg and
Vogelstein, 1983) and the FGFRI and FGFR4 samples were
hybridized with internal oligonucleotides that were end-labelled
with [y-32P]ATR. Hybridization was carried out as described by
Church and Gilbert (1984). The hybridized filters were analysed
by phosphoimaging. The values for FGFI, FGFRI and FGFR4
were normalized by dividing the signals by that for actin.
Immunoblotting
T'he specificity of the FGF1 antibody used in immunohistochem-
istry was determined by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) followed by Western blotting.
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Table 2 Expression of FGF1, FGFR1 and FGFR4 mRNA in separated breast
cell populations
Epithelial cells Myoepithelial cells
FGFla +++ +++
FGFRla ++ ++
FGFR4a ++ ++
aResults normalized to actin.
FGF1 and FGF2 peptides were mixed with SDS-PAGE sample
buffer andelectrophoresed on a 15% polyacrylamide gel. Separated
proteins were transferred onto a nitrocellulose membrane overnight
at 4°C. Non-specific binding sites were blocked with 3% milk
powder in PBS-T (PBS + 0.1% Tween 20) for 1 h at room temper-
ature before incubation of the membrane with either anti-FGFI
antibody or the same antiserum after it had been preincubated with
an excess of the FGF1 immunizing peptide. After washing, blots
were incubated with an anti-mouse IgG-peroxidase conjugate and
then washed five times in PBS-T. Bands were visualized using the
ECL method (Amersham). Purified populations of normal breast
epithelial and myoepithelial cells were lysed in SDS-PAGE sample
buffer and 40 gg ofprotein electrophoresed, blotted and stained in
the same manner as the standards above.
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RESULTS
Immunoblotting
The anti-FGF1 antibody recognized a protein band at 18 kDa
consistent with the molecular weight of recombinant FGF1 and
showed no cross-reactivity with FGF2 (Figure IA). The FGFI
band was absent when the membrane was incubated with anti-
FGF1 antibody, which hadbeen preincubated with an excess ofthe
FGF1 peptide used to raise the antibody (Figure IA). Western
hybridization of the separated normal epithelial and myoepithelial
cells with the same antibody to FGF1 showed both cell types to
have a band at 18 kDa (Figure IB).
FGF1, FGFR1 and FGFR4 expression by PCR
PCR conditions were optimized as previously described (Luqmani
et al, 1992a) to ensure that amplification was in the linear phase.
A total of35 cycles ofPCR forthe epithelial cell marker EMA and
the myoepitheial cell marker CALLA demonstrated the purity of
the separated cell populations (Gomm et al, 1995). Eighteen cycles
ofPCR were selected for the estimation ofactin levels and 28 and
40 cycles for FGF1, FGFR1 and FGFR4. All samples produced
the expected product size of 135 bp for FGF1, 465 bp for FGFR1
or 402 bp for FGFR4. In each case a single band corresponding to
319 bp was also seen for actin. Table 2 shows that both normal
B
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Figure 2 Peroxidase-haematoxylin staining of frozen sections of normal human breast. (A) Incubated with non-immune mouse IgG (original magnification,
x200). (B) Incubation with anti-FGF1 antibody results in intense staining of epithelial cells but not myoepithelial cells (original magnification, x200). (C) Higher
power photomicrograph shows FGF1 staining localized to cytoplasm and plasma membrane of normal epithelial cells (original magnification, x400).
(D) Incubated with antigen-absorbed anti-FGF1 antibody (original magnification, x200)
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Figure 3 Peroxidase-haematoxylin staining of frozen sections of malignant breast for FGF1. (A) DCIS showing no staining. (B) DCIS with scattered positively
stained cells. (C) Invasive ductal carcinoma with no immunoreactivity. (D) Invasive ductal carcinoma with scattered positivity. (E) Invasive ductal carcinoma with
pale, homogeneous FGF1 staining. (F) Invasive lobular carcinoma, with areas of pale FGF1 staining (original magnification of all sections, x200)
epithelial and myoepithelial cells express mRNA for FGF1,
FGFR1 and FGFR4.
Distribution of FGF1 staining
A total of 47 samples of normal breast were examined. These
consisted ofadjacent normal tissue taken from around carcinomas (n
= 24) and reduction mammoplasty tissue (n = 23). Staining was
confined to the epithelial cells in ducts and acini (Figure 2B) and
appeared at the light microscopy level to be associated with both the
cytoplasm and plasma membrane (Figure 2C). Myoepithelial cells
and stroma were essentially unstained. The number ofcells staining
and the intensity were variable. However, strongest staining appeared
tobeintheepithelialcells ofthemainducts. Positivelystainednormal
epithelial cells were also identified adjacent to neoplastic tissue and a
similar pattern of staining was observed. Using tissue sections of
normal breast, immunohistochemistry was performed after preincu-
bation of the antibody with a 100-fold excess of the immunizing
peptide (Figure 2D). By blocking anti-FGFI antibody binding with
the peptide, all FGF1 immunostaining was completely abolished.
Two examples of fibrocystic change and nine fibroadenomas were
examined and all showed epithelial cell staining for FGF1. One case
oflactating breastalso showed scatteredpositive stainingin theducts;
however, all lactating acini were negative forFGF1.
Nine cases of ductal carcinoma in situ (DCIS) were examined.
Three cases ofsolidDCIS andthree cases ofpurecomedocarcinoma
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Figure 4 Peroxidase-haematoxylin staining of unfixed frozen sections of invasive ductal carcinoma of the breast for FGF1. Adjacent normal duct (A and B) and
invasive cancer (C-F). A, C and E: Preincubation of sections with PBS for 2 h at 370 C. B, D and F: Preincubation of sections with PBS plus a cocktail of
protease inhibitors. (A) PBS treatment causes revealing of FGF1 epitope in myoepithelial cells of adjacent normal duct. (B) Inclusion of protease inhibitors
prevents FGF1 epitope on myoepithelial cells being accessible to anti-FGF1 antibody. (C) PBS treatment also results in FGF1 staining in the basement
membrane surrounding tumour islands. (D) With the addition of protease inhibitors no basement membrane FGF1 staining is seen. (E) After incubation in PBS
only, stroma adjacent to malignant epithelial cells is negative for FGF1. (F) Treatment with protease inhibitors prevents release of stromal FGF1 and thus
stabilizes FGF1 staining (original magnification of all sections, x200)
wereentirely negative (Figure 3A). Two cases ofcombined solid and
comedo DCIS and one micropapillary case had some scattered posi-
tive cells (Figure 3B). Out of a total of 30 cases of invasive ductal
carcinoma only one case showed pale but homogeneous staining of
neoplastic epithelial cells (Figure 3E) and three others showed areas
of scattered positivity (Figure 3D). The remainder were entirely
negative (Figure 3C). Ofthree cases of invasive lobular carcinoma,
all cases showed some areas ofpale staining (Figure 3F). One case
ofmucinous carcinoma was negative.
In view of previous studies showing a redistribution of FGF2
staining, dependent on the type oftissue fixation used (Hanneken
and Baird, 1992; Healy and Herman 1992; Ishigooka et al, 1992)
and because of our own experience in immunostaining for this
growth factor (results not shown), we examined the effects of
different fixation methods on FGFl localization. Cryostat
sections of both normal and malignant breast tissues fixed either
in acetone (50% followed by 100%) or 3.7% formaldehyde in
PBS alone, or formaldehyde followed by acetone gave the same
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pattern of FGF1 staining whichever method was used (results
not shown).
To determine whether the distribution ofFGF1 in the breast was
affected by the action of any endogenous proteases present in
either normal ormalignantbreasttissues we examined the effect of
incubating unfixed frozen sections at 37°C for 2 h in PBS, with
and without a cocktail of protease inhibitors (see method) on the
pattern of FGFI staining. We found that treatment with PBS at
pH 7.2 alone resulted in the appearance of FGF1 staining in the
myoepithelial cells of normal ducts adjacent to malignant tissue
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and this was sometimes accompanied by a loss of epithelial cell
staining (Figure 4A). This effect was not seen in normal ducts in
reduction mammoplasty specimens (Table 3). Residual myo-
epithelial cells and basement membrane surrounding islands of
malignant epithelial cells were also positive for FGF1 following
incubation in PBS at 37°C (Figure 4C).
When protease inhibitors were included in the PBS buffer the
myoepithelial cell and basement membrane staining was lost and
again FGF1 staining was only seen in normal epithelial cells
(Figure 4B and D). Thus, the presence of protease inhibitors
B
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Figure 5 Peroxidase-haematoxylin staining offrozen sections for FGFR1 and FGFR4. A, C and E: Normal breast. B, D and F: Invasive ductal carcinoma of
the breast. (A) Section of normal breast incubated with non-immune mouse IgG. (B) Section of malignant breast incubated with non-immune rabbit IgG.
(C and D) Sections incubated with anti-FGFR1 antibody show equivalent cytoplasmic staining of normal and malignant epithelial cells; myoepithelial cells exhibit
paler staining. (E and F) Sections incubated with anti-FGFR4 antibody show similar but paler staining distribution to anti-FGFR1 (original magnification of all
sections, x200).
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Table 3 Comparison of the effects of PBS and protease inhibitor treatments
on FGF1 immunostaining in normal vs adjacent normal breast ducts
Treatment Epithelial Myoepithellal Basement Stroma
cells cells membrane
Normal duct
None + - - -
PBS + - - -
Protease inhibitors + - - -
Adjacent normal duct
None + - - -
PBS +/- + + -
Protease inhibitors + - - +
prevented the FGF1 epitopes being accessible to the antibody on
the myoepithelial cells and the basement membrane, suggestive of
the presence of an endogenous protease associated with the
'normal' ducts adjacent to cancer tissue, which is active at a
neutral pH. An additional and significant effect of the incubation
of unfixed sections in PBS at 37°C in the presence of protease
inhibitors was the revelation ofFGFI staining in the stroma of all
the breast cancer samples treated, particularly in association with
malignant cells (Figure 4F). In no case did treatment with PBS or
protease inhibitors reveal additional FGF1 staining in the malig-
nant epithelial cells (Figure 4C-F) or in normal stroma. Incubation
of the anti-FGFI antibody with immunizing peptide caused a loss
of staining in all cases.
Immunohistochemistry for FGFR1 and FGFR4
All normal and benign breast tissue samples showed cytoplasmic
staining for FGFR1 in the epithelial cells (Figure SC). Myo-
epithelial cells were also stained but less strongly. No staining of
stromal cells was seen. This correlates with our previous PCR
results, which showed FGFR1 mRNA in microdissected keratin
19-expressing cells but not in breast stroma (Luqmani et al,
1992b). FGFR1 immunoreactivity was also found in the ductal and
acinar epithelial cells of lactating breast tissue. Sections of 16
invasive ductal and three invasive lobular carcinomas showed
homogeneous cytoplasmic staining of epithelial cells in all
sections (Figure 5D). Seven cases of DCIS were also positive, as
was the adjacent normal breast tissue present in 11 cases. The
pattern of FGFR4 immunoreactivity showed an identical distribu-
tion to that seen for FGFR1, but staining was not quite as intense
(Figure SE and F). There appeared to be no difference in staining
intensity between normal and malignant epithelial cells for both
FGF receptors.
DISCUSSION
This study represents the first detailed account of the localization
ofFGF1 and two of its receptors in breast tissue. Our results show
that the distribution of FGF1 is different between normal breast
and breast carcinoma: in the former it is present in the luminal
epithelial and myoepithelial cells, whereas in the latter it is also
seen in the basement membrane and stromal tissue surrounding the
malignant epithelial cells, which are essentially negative for
FGFI. Our findings also demonstrate the presence of receptors for
FGFI in both normal and malignant epithelial cells, suggesting
important autocrine and paracrine roles for this growth factor in
both the normal and neoplastic breast.
The pattern that emerges ofFGF1 localization in the breast is a
complex one butdoes give us some clues as to how the function of
this growth factor may be modified in the transition from the
normal to neoplastic state. Before incubation of unfixed frozen
sections in PBS at 37°C, with or without protease inhibitors,
although we were always able to demonstrate FGFI staining in
normal epithelial cells, we were unable to see FGF1 staining in the
myoepithelial cells, basement membrane and stromal tissue
surrounding carcinoma cells. As we have shown here, the differ-
ences seen in the distribution of FGF1 staining are not due to the
fixation method used nor could they have been due to artefacts of
freezing or the section cutting process (Clarke et al, 1993) as there
were major and specific changes in the FGF1 staining pattern
dependent on whether unfixed sections were treated with PBS
alone or PBS plus protease inhibitors, and especially between
cancer and normal breast tissues. It is more likely that these results
are because ofthe presence ofat least one endogenous protease in
malignant breast tissue, which is either absent or inactive in the
normal breast, as similar treatment caused no change in the
staining pattern in normal tissues.
The question now arises as to the nature and role of the
proteases involved in the sequestration and function of FGF1 in
breast cancer. The revealing of the FGF1 epitope in the myo-
epithelial cells in adjacent normal ducts but not normal ducts in
reduction mammoplasty tissue suggests a transition from a normal
to a preneoplastic state that involves the synthesis or activation of
aprotease. The metalloprotease stromelysin-1 has been detected in
myoepithelial cells surrounding preneoplastic lesions (Li et al,
1994) and matrilysin mRNA is expressed in both neoplastic breast
epithelial cells and non-neoplastic epithelial cells associated with
breast cancer (Wolf et al, 1993).
The stromal FGF1 staining seen only in association with malig-
nant areas following incubation with protease inhibitors was present
in all the cancers studied. As this staining was lost when sections
were incubated in PBS at 37°C this was indicative ofthe effect ofa
protease present in the stroma that acts to release FGF1 from its
storage sites. This may be a different protease to the one acting on
the ducts themselves. Many proteases, including the collagenases,
gelatinases, stromelysins, cathepsins and urokinase-type plas-
minogen activator are thought to have roles in cell-surface proteo-
lysis and invasion in breast cancer (Chen et al, 1994; Dickson et al,
1994), and more specific combinations ofprotease inhibitors will be
required to identify the nature ofthe enzymes involved in the FGF1
transition seen here. The presence of FGF1 in the stroma ofcancer
tissues also now explains the source of the released FGF1 that we
detected by bioassay of conditioned medium from breast tumour
biopsies (Smith et al, 1994). Stromal FGF1 may also be the ligand
for the FGF receptors expressed on malignant epithelial cells,
perhaps being released from storage by the action of a secreted
protease from the cancer cells themselves (Briozzo et al, 1991). We
have shown that both FGF1 and conditioned medium from breast
cancer biopsies is mitogenic for MCF7 and T47D breast cancer cell
lines (Smith et al, 1994; Johnston et al, 1995). Alternatively, cancer
cells may stimulate the surrounding fibroblasts toproduce their own
matrix proteases. Stromal cells surrounding invasive breast carci-
noma cells have been shown to synthesize the matrix mettllo-
proteinase, stromelysin-3 (Basset et al, 1991; Wolfet al, 1993), and
lung carcinoma cells release a factor that increases collagenase
expression in fibroblast cells (Kataoka et al, 1993).
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Our immunostaining results agree with work by Hughes and
Hall (1993), in which FGF1 was found to be localized to the glan-
dular epithelium ofnormal breast. But the pattem ofFGF1 distrib-
ution inbreast cancer seems to differ from that seen in othertissues
such as pancreas, brain and bladder where FGF1 was found to be
overexpressed in malignant tissue (Akutsu et al, 1991; Yamanaka
et al, 1993; Chopin et al, 1993). However, the mechanism ofFGF1
action in breast cancer may be different from these tissues.
Although our immunostaining results show a loss of FGF1
staining in the transition from normal to malignant epithelial cells,
this is replaced by intense stromal FGF1 staining closely associ-
ated with cancer cells which is sensitive to protease release.
As our previous results (Bansal et al, 1995) have suggested a
reduction in FGF1 synthesis in breast cancer compared with
normal breast tissue, this may mean thatthe FGF1 stromal staining
that we see in breast cancer sections may represent stored and not
newly synthesized FGF1. Similar to our immunostaining results
using tissue sections, we have found breast cancer cell lines to be
negative for FGF1 protein (Bansal et al, 1995), but it is possible
that FGF1 is released into the stroma at an early stage in the transi-
tion to malignancy. The alterations in the FGF1 staining pattem
that we see in the 'normal' ducts adjacent to cancercells following
PBS incubation may be representative of this change in FGF1
storage. Interestingly, Kandel et al (1991) found that there is a
switch from intracellular to extracellular FGF when normal fibro-
blasts undergo a progression to aggressive fibromatosis and
fibrosarcoma in transgenic mice.
The immunostaining of normal epithelial cells appears to be
both cytoplasmic and membrane associated. Thus the activity of
breast proteases may be twofold, firstly releasing FGF1 from its
site on the epithelial cell membrane when it becomes sequestered
by extracellular heparan sulphate proteoglycans (HSPGs) in the
stroma, then at a later stage the FGF1/HSPG complex could be
released from these storage sites allowing it to act on the extemal
high-affinity receptors that we have demonstrated to be present on
malignant cells. Such a specialized autocrine model for FGF
action has been proposed by Yeoman (1993). Both FGFl and
FGF2 have been found bound to HSPGs either on the cell surface
or in the extracellular matrix (Klagsbrun, 1990) and HSPG-bound
FGF1 has been shown to be 100x more mitogenic than heparin-
bound FGF1 (Gordon et al, 1989). FGF1 has been localized extra-
cellularly in vivo in the developing heart (Engelmann et al, 1993),
tooth (Cam et al, 1992), lungs, digestive system, CNS and eye (Fu
et al, 1991) where it is thought to act both as a paracrine growth
factor as well as stimulating capillary and neural invasion. Weiner
and Swain (1989) have shown that neonatal cardiac myocytes
deposit FGF1 into their extracellular matrix and FGFR1 transcipts
have been localized on developing cardiomyocytes (Engelman et
al, 1993). Thus, tumorogenesis may mimic development in its
mechanism ofFGF1 action.
FGF1 binds to FGFR1 and FGFR4 with similar high affinities
but FGFR4 has been shown to have a far stronger affinity for
FGF1 than any other member of the FGF family (Vainikka et al,
1992). About 10% of breast cancers have been shown to contain
amplified levels of the genes for FGFR1 (Adnane et al, 1991;
Jacquemier et al, 1994) and FGFR4 (Jaakkola et al, 1993).
Jacquemier et al (1994) also reported overexpression of FGFR1
mRNA in 14.5% ofbreast tumours and Penault-Llorca et al (1995)
found both FGFR1 and FGFR4 mRNA to be expressed at high
levels in 22% and 32% of breast cancers respectively. Our
immunostaining results, however, revealed homogeneous staining
forFGFR1 andFGFR4 protein in all breastepithelial cells, with no
apparent difference in staining intensity between normal and
malignant tissues. This agrees with ourresults using PCR to detect
FGFR mRNA in breast tissue extracts (Luqmani et al, 1992a;
1995). To our knowledge this is the first incidence of a growth
factor receptor that is present at equivalent levels in normal and
cancer tissue.
In conclusion, using immunohistochemistry for FGF1 and two
ofits receptors, together with a novel in situ assay for endogenous
proteases we have shown that the role ofthis growth factor in the
breast may depend on its location. It is possible that in the normal
gland FGF1 may be largely sequestered on epithelial cells and
unable to interact significantly with cell-surface receptors but once
released into the extracellular matrix by the inappropriate expres-
sion of proteases in breast cancer it becomes more bioavailable to
the epithelial cells.
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